Post-Transplant Lymphoproliferative Disorders: Management

Sambhavi Krishnamoorthy; Tarek Alhamad

doi:10.1007/978-3-031-13569-9_48

Post-Transplant Lymphoproliferative Disorders: Management

Sambhavi Krishnamoorthy, Tarek Alhamad

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of disorders that could present as indolent hyperplasia or aggressive lymphomas with distinct pathological subtypes and variable clinical presentations (Table 48.1). Increased incidence of late-onset EBV negative monomorphic PTLD associated with therapeutic immunosuppression has been observed with solid organ transplant recipients [1]. Advances in chemotherapeutic agents and cell therapy in the management of PTLD have made a significant impact on patient outcomes, given the significant morbidity and mortality related to this complication. In this chapter, we review a case of PTLD to understand the risks and benefits of treating this challenging disease and the serious impact it has in solid organ transplantation.

Original language	English
Title of host publication	Complications in Kidney Transplantation
Subtitle of host publication	A Case-Based Guide to Management
Publisher	Springer International Publishing
Pages	307-311
Number of pages	5
ISBN (Electronic)	9783031135699
ISBN (Print)	9783031135682
DOIs	https://doi.org/10.1007/978-3-031-13569-9_48
State	Published - Jan 1 2022

Keywords

Impact
Kidney transplant recipients
Management
Post-transplant lymphoproliferative disorders

Access to Document

10.1007/978-3-031-13569-9_48

Cite this

@inbook{9d8b5ae46f44492d8acdfa9145a38766,

title = "Post-Transplant Lymphoproliferative Disorders: Management",

abstract = "Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of disorders that could present as indolent hyperplasia or aggressive lymphomas with distinct pathological subtypes and variable clinical presentations (Table 48.1). Increased incidence of late-onset EBV negative monomorphic PTLD associated with therapeutic immunosuppression has been observed with solid organ transplant recipients [1]. Advances in chemotherapeutic agents and cell therapy in the management of PTLD have made a significant impact on patient outcomes, given the significant morbidity and mortality related to this complication. In this chapter, we review a case of PTLD to understand the risks and benefits of treating this challenging disease and the serious impact it has in solid organ transplantation.",

keywords = "Impact, Kidney transplant recipients, Management, Post-transplant lymphoproliferative disorders",

author = "Sambhavi Krishnamoorthy and Tarek Alhamad",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.",

year = "2022",

month = jan,

day = "1",

doi = "10.1007/978-3-031-13569-9_48",

language = "English",

isbn = "9783031135682",

pages = "307--311",

booktitle = "Complications in Kidney Transplantation",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Post-Transplant Lymphoproliferative Disorders

T2 - Management

AU - Krishnamoorthy, Sambhavi

AU - Alhamad, Tarek

N1 - Publisher Copyright: © The Author(s), under exclusive license to Springer Nature Switzerland AG 2022.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of disorders that could present as indolent hyperplasia or aggressive lymphomas with distinct pathological subtypes and variable clinical presentations (Table 48.1). Increased incidence of late-onset EBV negative monomorphic PTLD associated with therapeutic immunosuppression has been observed with solid organ transplant recipients [1]. Advances in chemotherapeutic agents and cell therapy in the management of PTLD have made a significant impact on patient outcomes, given the significant morbidity and mortality related to this complication. In this chapter, we review a case of PTLD to understand the risks and benefits of treating this challenging disease and the serious impact it has in solid organ transplantation.

AB - Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of disorders that could present as indolent hyperplasia or aggressive lymphomas with distinct pathological subtypes and variable clinical presentations (Table 48.1). Increased incidence of late-onset EBV negative monomorphic PTLD associated with therapeutic immunosuppression has been observed with solid organ transplant recipients [1]. Advances in chemotherapeutic agents and cell therapy in the management of PTLD have made a significant impact on patient outcomes, given the significant morbidity and mortality related to this complication. In this chapter, we review a case of PTLD to understand the risks and benefits of treating this challenging disease and the serious impact it has in solid organ transplantation.

KW - Impact

KW - Kidney transplant recipients

KW - Management

KW - Post-transplant lymphoproliferative disorders

UR - http://www.scopus.com/inward/record.url?scp=85173313664&partnerID=8YFLogxK

U2 - 10.1007/978-3-031-13569-9_48

DO - 10.1007/978-3-031-13569-9_48

M3 - Chapter

AN - SCOPUS:85173313664

SN - 9783031135682

SP - 307

EP - 311

BT - Complications in Kidney Transplantation

PB - Springer International Publishing

ER -

Post-Transplant Lymphoproliferative Disorders: Management

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this